PDGF induced cell homing

Patent metadata

Field	Value
Publication number	US-9603899-B2
Application number	US-201113877272-A
Country	US
Kind code	B2
Filing date	Oct 3, 2011
Priority date	Oct 1, 2010
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

Provided is a method of causing a cell to migrate to a scaffold. Also provided is a method of treating a mammal that has a tissue defect. Further provided is a tissue scaffold comprising platelet-derived growth factor (PDGF). Additionally, a method of making a tissue scaffold capable of recruiting a cell is provided.

First claim

What is claimed is:

1. A method of treating a subject having tissue damage, the method comprising:
implanting a scaffold comprising an effective amount of platelet-derived growth factor-BB (PDGF-BB) at or near a damaged tissue selected from damaged dental pulp or damaged dentin;
wherein,
the scaffold comprises fibrin or collagen;
the scaffold does not comprise a transplanted cell prior to implantation in the subject;
the PDGF-BB is present in the scaffold at a concentration of about 10 ng/ml to 1,000 ng/ml; and
the effective amount of PDGF-BB recruits alveolar stem cells into the scaffold to regenerate dental pulp or dentin at or near the damaged tissue.

2. The method of claim 1 , wherein the scaffold further comprises at least one of PDGF-AA and PDGF-AB.

3. The method of claim 1 , wherein the scaffold comprises a composition comprising PDGF-BB and the PDGF-BB is present in the composition at a concentration of about 10 ng/ml to about 100 ng/ml.

4. The method of claim 1 , wherein the scaffold comprises a composition comprising PDGF-BB and the PDGF-BB is present in the composition at a concentration of 250 ng/ml.

5. The method of claim 1 , wherein the scaffold comprises at least two layers.

6. The method of claim 5 , wherein at least one layer comprises PDGF-BB.

7. The method of claim 6 , wherein the PDGF-BB is encapsulated in a microsphere.

8. The method of claim 1 , wherein the PDGF-BB is encapsulated in a microsphere.

9. The method of claim 1 , wherein the scaffold does not contain a bioactive molecule other than PDGF-BB.

10. The method of claim 1 , wherein the scaffold does not contain an additional chemotactic growth factor, osteogenic growth factor, dentinogenic growth factor, amelogenic growth factor, or cementogenic growth factor.

11. The method of claim 1 , wherein the scaffold further comprises an osteogenic growth factor, dentinogenic growth factor, amelogenic growth factor, or cementogenic growth factor.

12. The method of claim 1 , wherein dental pulp and dentin are regenerated at or near the dental tissue defect.

13. The method of claim 1 , wherein the scaffold comprises collagen in a substantially gelled phase.

14. The method of claim 1 , wherein the scaffold comprises collagen gel.

15. The method of claim 1 , wherein PDGF-BB is present in the scaffold at a concentration of about 10 ng/ml, about 20 ng/ml, about 30 ng/ml, about 40 ng/ml, about 50 ng/ml, about 60 ng/ml, about 70 ng/ml, about 80 ng/ml, about 90 ng/ml, about 100 ng/ml, about 150 ng/ml, about 200 ng/ml, about 250 ng/ml, or about 300 ng/ml.

Assignees

• Mao Jeremy J
• Zhao Wenli
• Univ Columbia

Inventors

• Mao Jeremy J
• Zhao Wenli

Classifications

• A61K38/1858 Primary

  Platelet-derived growth factor [PDGF] · CPC title

• C12N2501/15

  Transforming growth factor beta (TGF-β) · CPC title

• A61K9/00

  Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title

• C12N2501/105

  Insulin-like growth factors [IGF] · CPC title

• C12N2533/40

  Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers · CPC title